Choshi, Japan

Takanori Miyashita


Average Co-Inventor Count = 5.3

ph-index = 4

Forward Citations = 93(Granted Patents)


Company Filing History:


Years Active: 1991-2003

Loading Chart...
7 patents (USPTO):Explore Patents

Title: Takanori Miyashita: Innovator in Pharmaceutical Crystallization

Introduction

Takanori Miyashita is a notable inventor based in Choshi, Japan. He has made significant contributions to the field of pharmaceutical crystallization, holding a total of seven patents. His work focuses on the development of high-purity and stable crystalline forms of nucleotides, which are essential in the pharmaceutical industry.

Latest Patents

One of Takanori Miyashita's latest patents involves the creation of dinucleotide tetraphosphate crystals. This invention is directed to crystals of P-(2′-deoxycytidine 5′-)P-(uridine 5′-)tetraphosphate (dCP4U) or a salt thereof. The process for producing these crystals includes reacting uridine 5′-monophosphate (UMP), 2′-deoxycytidine 5′-monophosphate (dCMP), diphenyl phosphorochloridate (DPC), and pyrophosphate (PPi). The resulting dCP4U crystals exhibit high purity, stability, and non-hygroscopic properties compared to freeze-dried products. This makes them a valuable raw material for pharmaceutical preparations. The process also allows for the use of inexpensive UMP as a raw material, achieving high yields suitable for large-scale synthesis.

Career Highlights

Throughout his career, Takanori Miyashita has worked with prominent companies in the pharmaceutical sector, including Yoshitomi Pharmaceutical Industries, Ltd. and Yamasa Corporation. His expertise in crystallization and pharmaceutical processes has positioned him as a key figure in the development of innovative solutions in the industry.

Collaborations

Takanori has collaborated with notable colleagues such as Shinji Sakata and Akira Matsuda. Their combined efforts have contributed to advancements in the field of pharmaceutical sciences.

Conclusion

Takanori Miyashita's innovative work in the development of dinucleotide tetraphosphate crystals showcases his significant contributions to the pharmaceutical industry. His patents reflect a commitment to enhancing the quality and efficiency of pharmaceutical raw materials.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…